---
title: "NervGen Pharma ernennt Adam Rogers zum CEO"
description: "NervGen Pharma Corp. has appointed Adam Rogers, MD, as the new President and Chief Executive Officer, effective immediately. Rogers will lead the company in advancing its main product NVG-291 and will"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/275312873.md"
published_at: "2026-02-09T12:01:21.000Z"
---

# NervGen Pharma ernennt Adam Rogers zum CEO

> NervGen Pharma Corp. has appointed Adam Rogers, MD, as the new President and Chief Executive Officer, effective immediately. Rogers will lead the company in advancing its main product NVG-291 and will be responsible for the strategic direction in therapies for spinal cord injuries.

NervGen Pharma Corp. hat Adam Rogers, MD, zum neuen Präsidenten und Chief Executive Officer ernannt. Rogers übernimmt die Leitung des Unternehmens mit sofortiger Wirkung und wird die Weiterentwicklung des Hauptprodukts NVG-291 sowie die strategische Ausrichtung im Bereich der Therapien für Rückenmarksverletzungen verantworten. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NervGen Pharma Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9650926-en) on February 09, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [NGEN.US - NervGen Pharma](https://longbridge.com/en/quote/NGEN.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| NervGen Pharma Reports Positive Results from Phase 1b/2a CONNECT Study in Chronic Spinal Cord Injury | NervGen Pharma Corp. announced positive results from its Phase 1b/2a CONNECT Study for chronic spinal cord injury. The c | [Link](https://longbridge.com/en/news/275600172.md) |
| Natco Pharma Says API Unit In Chennai Receives Establishment Inspection Report From U.S. FDA | Natco Pharma Ltd :NATCO PHARMA - API UNIT IN CHENNAI RECEIVES ESTABLISHMENT INSPECTION REPORT FROM U.S. FDANATCO PHARMA  | [Link](https://longbridge.com/en/news/275846236.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.